RxSight, Inc.
RXST · Price history
Price at last available close
$4.90
+$0.13 (+2.73%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About RxSight, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal.
How they make money
RxSight utilizes a razor and razor blade business model. The company sells its Light Delivery Device (LDD) to ophthalmology practices, which then creates an ongoing demand for its proprietary Light Adjustable Lens (LAL) products that are implanted during cataract surgery and adjusted post-operatively.
Products & services
The RxSight system consists of the Light Adjustable Lens (LAL/LAL+), the Light Delivery Device (LDD) used for post-operative adjustments, and related accessories.
Brands & revenue mix
The core premium cataract technology brand.
Separate brand revenue is not available in this research.Source
The device used to adjust the LAL post-surgery.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company does not disclose specific customer concentration figures in its 2025 annual report.
Suppliers, materials & equipment
- Contract Manufacturers — The company relies on third-party contract manufacturers for the production of its LDD and LAL components; specific supplier names are not disclosed.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
31
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
39
Poor
Financial Strength
42
Business Quality / Moat
58
Management
40
Growth Quality
15
Risk / Durability
14
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
32
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
46/100
Building Historical Record
Model Score 46/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Asset quality scores strongly
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for RXST
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving RXST's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can RXST fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does RXST's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for RXST to reach sustainable profitability?
- •What future growth or profitability would be needed to justify RXST's current valuation?
Essential Investment Snapshot
Wall Street Score
31
Opportunity Score
32
Market Cap
$203.8M
P/E Ratio
-4.1
EPS
$-1.13
52-Week High
$13.22
52-Week Low
$4.40
Beta
1.14
Analyst Target
$6.38
Shares Outstanding
41.2M
Total Revenue
$127.6M
Total Debt
$10.6M
Dividend
No current dividend
Liquidation Value / Share
$6.40
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for RXST
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-1204.8x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on RXST.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary adjustable intraocular lens technology.
- +Established installed base of LDDs.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Dependence on the commercial success of the RxSight system.
- −Risks associated with international expansion and regulatory approvals.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
31
Oct 1, 2026
Change
Unchanged
Current Score
31
Oct 19, 2026
Category Changes
RXST score was unchanged.
Projected Score
Projected Score
32
Projected Change
+0.8 points
Preliminary comparable-period financial changes suggest improvement of approximately 0.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$4.90
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $127.6M | $134.5M | $139.9M | $89.1M | ···· | ···· | ···· | ···· |
| Cost of Revenue | $28.7M | $31.5M | $41.0M | $35.3M | ···· | ···· | ···· | ···· |
| Gross Profit | $98.9M | $103.0M | $98.9M | $53.8M | ···· | ···· | ···· | ···· |
| Research & Development | $36.7M | $38.5M | $34.4M | $29.1M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $117.3M | $112.6M | $101.4M | $74.8M | ···· | ···· | ···· | ···· |
| Operating Expenses | $154.0M | $151.2M | $135.8M | $103.8M | ···· | ···· | ···· | ···· |
| EBITDA | -$43.3M | -$35.6M | -$23.8M | -$41.0M | ···· | ···· | ···· | ···· |
| Operating Income | -$55.1M | -$48.2M | -$36.9M | -$50.1M | ···· | ···· | ···· | ···· |
| Interest Expense | $15K | $40K | $21K | $3.3M | ···· | ···· | ···· | ···· |
| Income Before Tax | -$46.8M | -$38.9M | -$27.4M | -$48.6M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $110K | $66K | $50K | $20K | ···· | ···· | ···· | ···· |
| Net Income | -$46.9M | -$38.9M | -$27.5M | -$48.6M | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.13 | $-0.95 | $-0.71 | $-1.41 | ···· | ···· | ···· | ···· |
| Basic Shares | 41.49M | 41.18M | 38.87M | 34.46M | ···· | ···· | ···· | ···· |
| Diluted Shares | 41.49M | 41.18M | 38.87M | 34.46M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$33.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.29
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-9.7%
Cash Change
-66.9%
Margin Change
-0.8 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels. Pressure indicators included EPS growth, cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 0.3%. EPS was essentially unchanged. Cash declined 66.9%. Total debt declined 9.7%. Net income margin declined by 0.8 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
RxSight (NASDAQ:RXST) and Organigram Global (NASDAQ:OGI) Financial Survey
Rumor Mill · RXST
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial